<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04562337</url>
  </required_header>
  <id_info>
    <org_study_id>ES-SCLC-1st-IIT-SHR1316-CRT</org_study_id>
    <nct_id>NCT04562337</nct_id>
  </id_info>
  <brief_title>A Phase II Clinical Study of SHR-1316 Combined With Chemotherapy and Chest Radiotherapy in Extensive Small Cell Lung Cancer</brief_title>
  <official_title>Director of Shandong Cancer Hospital and Institute</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shandong Cancer Hospital and Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shandong Cancer Hospital and Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a one arm, open, single center phase II study. The main purpose of this study&#xD;
      was to evaluate the tolerance and preliminary efficacy of shr1316 combined with chest&#xD;
      radiotherapy after induction therapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2020</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">September 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall survival （OS）</measure>
    <time_frame>Up to approximately 36 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>progression-free survival (PFS)</measure>
    <time_frame>Up to approximately 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>Up to approximately 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>disease control rate (DCR)</measure>
    <time_frame>Up to approximately 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>Up to approximately 36 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">67</enrollment>
  <condition>Extensive-stage Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>SHR1316+Chemotherapy +Radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Paiticipant receive SHR-1316 、Chemotherapy and Radiotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR1316</intervention_name>
    <description>Anti-PD-L1 antibody</description>
    <arm_group_label>SHR1316+Chemotherapy +Radiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chemotherapy</intervention_name>
    <description>Carboplatin</description>
    <arm_group_label>SHR1316+Chemotherapy +Radiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chemotherapy</intervention_name>
    <description>etoposide</description>
    <arm_group_label>SHR1316+Chemotherapy +Radiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation therapy</intervention_name>
    <description>thoracic radiation therapy ,TRT</description>
    <arm_group_label>SHR1316+Chemotherapy +Radiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Confirmed diagnosis of Extensive small cell lung cancer&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group performance status (PS) of 0 to 1&#xD;
&#xD;
          -  18 to 75 years old&#xD;
&#xD;
          -  The function of vital organs meets the following requirements. WBC ≥ 3.0 × 109/L,&#xD;
             ANC≥1.5×10^9/L, PLT≥100×10^9/L, Hb≥9g/dL, ALT and AST ≤2.5 times ULN, TBIL ≤1.5 x ULN,&#xD;
             CREA ≤1.5 times ULN or CCr≥60mL/min. INR≤1.5 x ULN, APTT ≤1.5 x ULN&#xD;
&#xD;
          -  have not received first-line systemic therapy or immunosuppressive therapy for es-sclc&#xD;
&#xD;
          -  The estimated survival period is more than 8 weeks&#xD;
&#xD;
          -  Measurable lesions outside of the field of chest radiotherapy(iRECIST)&#xD;
&#xD;
          -  Signed written informed consent prior to study entry&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Active or untreated CNS metastases&#xD;
&#xD;
          -  Leptomeningeal diseases&#xD;
&#xD;
          -  Uncontrolled or symptomatic hypercalcemia&#xD;
&#xD;
          -  Active, known or suspected autoimmune diseases&#xD;
&#xD;
          -  have received any T cell co stimulation or immune checkpoint therapy&#xD;
&#xD;
          -  Corticosteroids (&gt; 10 mg / day prednisone or equivalent) or other immunosuppressants&#xD;
             were used within 14 days before the first dose of study drug.&#xD;
&#xD;
          -  Subjects had active infections.&#xD;
&#xD;
          -  Failing to properly control the clinical symptoms or disease of the heart&#xD;
&#xD;
          -  Patients who have previously received allogeneic bone marrow transplantation or solid&#xD;
             organ transplantation&#xD;
&#xD;
          -  Known to be allergic to the study drug or excipients, known to have a serious allergic&#xD;
             reaction to any kind of monoclonal antibody; have a history of hypersensitivity to&#xD;
             cisplatin or etoposide&#xD;
&#xD;
          -  According to the researcher's judgment, there are other factors that may lead to the&#xD;
             termination of the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>JinMing Yu, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shandong Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>JinMing Yu, PhD</last_name>
    <phone>+8613806406293</phone>
    <email>jn7984729@public.jn.sd.cn</email>
  </overall_contact>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>August 28, 2020</study_first_submitted>
  <study_first_submitted_qc>September 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 24, 2020</study_first_posted>
  <last_update_submitted>September 18, 2020</last_update_submitted>
  <last_update_submitted_qc>September 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shandong Cancer Hospital and Institute</investigator_affiliation>
    <investigator_full_name>Jinming Yu</investigator_full_name>
    <investigator_title>President of Shandong Cancer Hospital and Institute</investigator_title>
  </responsible_party>
  <keyword>SHR1316, Chemotherapy, Radiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

